We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
TIDMGSK
RNS Number : 3723U
GlaxoSmithKline PLC
28 July 2020
GlaxoSmithKline plc (the ' Company ')
PDMR Transaction
On 19 February 2020, GSK announced the vesting of awards over Ordinary Shares on 17 February 2020 made to Persons Discharging Managerial Responsibilities ('PDMRs') in 2017 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'), with the exception of the Chief Executive Officer ('CEO'). It was announced at that time that the Remuneration Committee determined that the normal three-year vesting period for the award made to the CEO should end in July 2020 on the third anniversary of the award, and thereafter the additional two-year vesting period applicable to Executive Directors would apply to her award in accordance with the terms of the 2017 Remuneration Policy. This notification sets out the details of the CEO's 2017 PSP award which vested on 27 July 2020, the third anniversary of the award. These shares are now subject to an additional two-year vesting period.
The same performance measure vesting details previously announced for the 2017 PSP awards apply to the CEO's PSP award and are set out below for ease of reference. The three-year performance period for the 2017 awards commenced on 1 January 2017 and ended on 31 December 2019.
Outcome and Vesting Level Portion Measure and Outcome % of maximum % of award of the Award ------------------------------------------- ------------- ----------- Adjusted Free Cash Flow - For the three-year period, the Company achieved Adjusted Free Cash Flow calculated in accordance with the principles for the measure of GBP13bn, which is above the level of GBP12.95bn required for maximum vesting. Adjustments to the original target and vesting schedule were communicated 1/3rd in the 2018 Annual Report. 100 33.333 ------------------------------------------- ------------- ----------- Total Shareholder Return - For the three years ending 31 December 2019, the Company's Total Shareholder Return ranked 8th, which is below the threshold vesting level against a comparator group of 10 global pharmaceutical 1/3rd companies including GSK. 0 0 ------------------------------------------- ------------- ----------- R&D New Products - For the three-year period, the Company achieved New Product sales calculated in accordance with the principles for the measure of GBP7.254bn, which is above the level of GBP5.099bn required for maximum vesting. The threshold vesting 1/3rd level was GBP4.172bn. 100 33.333 ------------------------------------------- ------------- ----------- Total vesting for 2017 award 66.666% Lapsed 33.334% -------------------------------------------------------------------- -----------
The notification that follows shows the number of shares which vested, including dividends accrued, on 27 July 2020. The balance of the award has lapsed. The closing price of Ordinary Shares of GlaxoSmithKline plc on 27 July 2020 was GBP15.834.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA') ==== =========================================================================================== a) Name Ms E N Walmsley ==== ======================================== ================================================= b) Position/status Chief Executive Officer ==== ======================================== ================================================= c) Initial notification/ Initial notification amendment ==== ======================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== =========================================================================================== a) Name GlaxoSmithKline plc ==== ======================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== =========================================================================================== a) Description of Ordinary Shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ======================================== ================================================= b) Nature of the The number of Ordinary Shares vesting on transaction awards granted in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================= GBP0.00 277,623 =================================================================== ======================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================ ============================== e) Date of the transaction 2020-07-27 ==== ======================================== ================================================= f) Place of the N/A transaction ==== ======================================== =================================================
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHZVLFLBDLLBBB
(END) Dow Jones Newswires
July 28, 2020 10:23 ET (14:23 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions